NO328349B1 - Kombinasjon av riluzol og α-tokoferol, anvendelse av denne og et farmasoytisk preparat omfattende en slik kombinasjon - Google Patents
Kombinasjon av riluzol og α-tokoferol, anvendelse av denne og et farmasoytisk preparat omfattende en slik kombinasjon Download PDFInfo
- Publication number
- NO328349B1 NO328349B1 NO20012308A NO20012308A NO328349B1 NO 328349 B1 NO328349 B1 NO 328349B1 NO 20012308 A NO20012308 A NO 20012308A NO 20012308 A NO20012308 A NO 20012308A NO 328349 B1 NO328349 B1 NO 328349B1
- Authority
- NO
- Norway
- Prior art keywords
- riluzole
- combination
- tocopherol
- patients
- pharmaceutically acceptable
- Prior art date
Links
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 title claims abstract description 30
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 229960004181 riluzole Drugs 0.000 title claims abstract description 26
- 229940087168 alpha tocopherol Drugs 0.000 title claims abstract description 15
- 229960000984 tocofersolan Drugs 0.000 title claims abstract description 15
- 235000004835 α-tocopherol Nutrition 0.000 title claims abstract description 15
- 239000002076 α-tocopherol Substances 0.000 title claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000003085 diluting agent Substances 0.000 claims abstract description 5
- 239000002671 adjuvant Substances 0.000 claims abstract description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000004202 respiratory function Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- VYEYJCBEXFTGBN-UHFFFAOYSA-N acetic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 VYEYJCBEXFTGBN-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940072169 rilutek Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fats And Perfumes (AREA)
- External Artificial Organs (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Cosmetics (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9814250A FR2785808B1 (fr) | 1998-11-13 | 1998-11-13 | Association riluzole et alpha-tocopherol |
| PCT/FR1999/002753 WO2000028992A1 (fr) | 1998-11-13 | 1999-11-09 | Association riluzole et alpha-tocopherol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20012308L NO20012308L (no) | 2001-05-10 |
| NO20012308D0 NO20012308D0 (no) | 2001-05-10 |
| NO328349B1 true NO328349B1 (no) | 2010-02-01 |
Family
ID=9532674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012308A NO328349B1 (no) | 1998-11-13 | 2001-05-10 | Kombinasjon av riluzol og α-tokoferol, anvendelse av denne og et farmasoytisk preparat omfattende en slik kombinasjon |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6642262B2 (de) |
| EP (1) | EP1128829B1 (de) |
| JP (1) | JP4693241B2 (de) |
| KR (1) | KR100641472B1 (de) |
| CN (1) | CN1177587C (de) |
| AT (1) | ATE295168T1 (de) |
| AU (1) | AU776242B2 (de) |
| BR (1) | BR9915292A (de) |
| CA (1) | CA2350671C (de) |
| CZ (1) | CZ298808B6 (de) |
| DE (1) | DE69925301T2 (de) |
| DK (1) | DK1128829T3 (de) |
| EA (1) | EA003671B1 (de) |
| ES (1) | ES2239858T3 (de) |
| FR (1) | FR2785808B1 (de) |
| HK (1) | HK1041220B (de) |
| HU (1) | HU226067B1 (de) |
| IL (1) | IL142708A0 (de) |
| NO (1) | NO328349B1 (de) |
| PT (1) | PT1128829E (de) |
| TR (1) | TR200101346T2 (de) |
| WO (1) | WO2000028992A1 (de) |
| ZA (1) | ZA200103810B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2786101B1 (fr) * | 1998-11-24 | 2002-07-05 | Aventis Laboratoire | Utilisation de la nicergoline dans le traitement de la spasticite |
| CA2625341A1 (en) * | 2005-10-18 | 2007-04-26 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis |
| US20070099156A1 (en) * | 2005-10-28 | 2007-05-03 | Jeff Wagner | Self-etching dental primer compositions and methods and systems utilizing such compositions |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| WO2014145776A2 (en) * | 2013-03-15 | 2014-09-18 | Baylor College Of Medicine | Msp and its receptors in the therapy of amyotrophic lateral sclerosis |
| CN114344297B (zh) * | 2022-03-01 | 2024-05-14 | 暨南大学 | 利鲁唑在治疗少精症中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
| US5843641A (en) * | 1993-02-26 | 1998-12-01 | Massachusetts Institute Of Technology | Methods for the daignosis, of familial amyotrophic lateral sclerosis |
| US6380252B1 (en) * | 1996-07-05 | 2002-04-30 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1 |
| US5780489A (en) * | 1996-08-21 | 1998-07-14 | Brooks; Benjamin Rix | Method for treating amyotrophic lateral sclerosis |
| JP3889844B2 (ja) * | 1997-02-10 | 2007-03-07 | 龍兒 梶 | 筋萎縮性側索硬化症治療剤 |
| FR2782008B1 (fr) * | 1998-08-07 | 2003-04-25 | Sod Conseils Rech Applic | Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique |
-
1998
- 1998-11-13 FR FR9814250A patent/FR2785808B1/fr not_active Expired - Fee Related
-
1999
- 1999-11-09 BR BR9915292-4A patent/BR9915292A/pt not_active Application Discontinuation
- 1999-11-09 DE DE69925301T patent/DE69925301T2/de not_active Expired - Lifetime
- 1999-11-09 ES ES99972101T patent/ES2239858T3/es not_active Expired - Lifetime
- 1999-11-09 KR KR1020017005912A patent/KR100641472B1/ko not_active Expired - Fee Related
- 1999-11-09 JP JP2000582039A patent/JP4693241B2/ja not_active Expired - Fee Related
- 1999-11-09 HK HK02102998.6A patent/HK1041220B/zh not_active IP Right Cessation
- 1999-11-09 IL IL14270899A patent/IL142708A0/xx not_active IP Right Cessation
- 1999-11-09 HU HU0105301A patent/HU226067B1/hu not_active IP Right Cessation
- 1999-11-09 EA EA200100530A patent/EA003671B1/ru not_active IP Right Cessation
- 1999-11-09 WO PCT/FR1999/002753 patent/WO2000028992A1/fr not_active Ceased
- 1999-11-09 DK DK99972101T patent/DK1128829T3/da active
- 1999-11-09 AU AU11655/00A patent/AU776242B2/en not_active Ceased
- 1999-11-09 CN CNB998131903A patent/CN1177587C/zh not_active Expired - Fee Related
- 1999-11-09 CZ CZ20011561A patent/CZ298808B6/cs not_active IP Right Cessation
- 1999-11-09 EP EP99972101A patent/EP1128829B1/de not_active Expired - Lifetime
- 1999-11-09 PT PT99972101T patent/PT1128829E/pt unknown
- 1999-11-09 CA CA2350671A patent/CA2350671C/fr not_active Expired - Fee Related
- 1999-11-09 AT AT99972101T patent/ATE295168T1/de active
- 1999-11-09 TR TR2001/01346T patent/TR200101346T2/xx unknown
-
2001
- 2001-05-10 ZA ZA200103810A patent/ZA200103810B/en unknown
- 2001-05-10 NO NO20012308A patent/NO328349B1/no not_active IP Right Cessation
- 2001-05-11 US US09/854,318 patent/US6642262B2/en not_active Expired - Lifetime
-
2003
- 2003-02-18 US US10/369,151 patent/US20030125363A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McConville et al. | Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders | |
| Sindrup et al. | The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms | |
| Reljanovic et al. | Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II) | |
| Siris et al. | Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial | |
| Maxwell et al. | Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity | |
| Feighner et al. | Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression | |
| EP4110310A1 (de) | Verfahren zur behandlung des tuberösen sklerosekomplexes mit cannabidiol und everolimus | |
| Donlon et al. | Haloperidol for acute schizophrenic patients: An evaluation of three oral regimens | |
| JP4411414B2 (ja) | 糖尿病性神経障害の治療に対する組成物及びその方法 | |
| KR101841442B1 (ko) | 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법 | |
| EP3579830A1 (de) | Cannabinoidhaltige fettsäureformulierungen zur behandlung von erkrankungen des nervensystems | |
| Dehlin et al. | A double‐blind comparison of alaproclate and placebo in the treatment of patients with senile dementia | |
| Hale | A review of the safety and tolerability of sertindole | |
| Lindborg et al. | Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients | |
| WO2008085567A1 (en) | Methods of using low-dose doxepin for the improvement of sleep | |
| EP0282818B1 (de) | Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression | |
| Zoma et al. | Effects of combined use of sildenafil citrate (Viagra) and 17β-estradiol on ovine coronary and uterine hemodynamics | |
| AU608048B2 (en) | Use of 2-amino-6-(trifluoromethoxy)benzothiazole for the treatment of schizophrenia | |
| JP4693241B2 (ja) | リルゾールおよびα−トコフェロールの組み合わせ剤 | |
| Shur et al. | Failure of mianserin to affect autonomic function in the pupils of depressed patients | |
| EP0279867A2 (de) | Verwendung von Vitamin-E und Vitamin-E-Kombination mit nichtsteroidalen Antirheumatika und Schmerzmittel zur Behandlung von rheumatischen Erkrankungen | |
| Leinonen et al. | Serum mianserin and ageing | |
| Pflug et al. | A double‐blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia | |
| Hrdina et al. | Antidepressant plasma levels and clinical response in depressed patients treated with oxaprotiline and doxepin | |
| US5023270A (en) | Antidepressant method of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |